论文部分内容阅读
目的 评价阿苯达唑免疫脂质体 (IL - Alb)治疗小鼠细粒棘球蚴病的效果。 方法 每只小鼠感染约 10 0 0个细粒棘球绦虫原头蚴 ,80天后随机分为 5组 ,4个治疗组分别给予阿苯达唑 (Alb)、阿苯达唑脂质体 (L-Alb)、阿苯达唑亚砜脂质体 (L - Albso)及 IL - Alb,按原药 10 0 m g/ (kg.d)× 5 d ip,连续 3个疗程 ,另 1组为对照组。治疗效果按囊重抑制率、常规病理切片、超微结构及高效液相色谱法测定囊药含量 4个指标综合评价。 结果 L - Alb治疗组 ,囊重抑制率为 80 .3% ,囊药含量为 2 .18μg/ g,优于 Alb组囊重抑制率为 6 1.2 % ,囊药含量为 0 .76μg/ g;而 IL- Alb组的囊重抑制率为 91.45 % ,囊药含量为 5 .15 μg/ g。组织病理损伤以 IL- Alb组较重。 结论 免疫脂质体作为 Alb载体 ,可增加药物的靶特异性 ,提高 Alb治疗细粒棘球蚴的疗效。
Objective To evaluate the efficacy of albendazole immunoliposomes (IL - Alb) in the treatment of mice with hydatid disease. METHODS: Each mouse was infected with about 100 Echinococcus granulosus of Echinococcus granulosus and then randomly divided into 5 groups after 80 days. The four treatment groups were given albendazole (Alb), albendazole liposomes L-Alb, L-Albso and IL-Alb were given for 3 consecutive courses of treatment according to the original drug dose of 10 0 mg / (kg · d) × 5 d ip Control group. Therapeutic effect according to the inhibition rate of the capsule, routine pathology, ultrastructure and HPLC determination of cystic drug content of four indicators of comprehensive evaluation. Results The inhibitory rate of capsule weight was 80.3% and the volume of cystic drug was 2.18μg / g in L - Alb treatment group. The inhibition rate of cystic weight in Alb group was 6 1.2%, and the cystic drug content was 0.76μg / g. The IL-Alb group, the capsule weight inhibition rate was 91.45%, cystic drug content of 5.15 μg / g. Histopathological damage to IL-Alb group heavier. Conclusion Immunoliposomes as Alb carrier can increase the target specificity of drugs and improve the therapeutic effect of Alb in the treatment of Echinococcus granulosus.